Skip to main content

Table 3 ECMO-associated complications and major adverse events

From: Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study

 

All

(n = 254)

CTRL

(n = 200)

EXT

(n = 54)

P-value

Infectious complications

    

 Nosocomial infections

172 (68)

147 (74)

25 (46)

< 0.01

  Ventilator-associated pneumonia

147 (58)

127 (64)

20 (37)

< 0.01

  Bloodstream infection

59 (23)

51 (26)

8 (15)

0.10

  Urinary tract infection

43 (17)

37 (18)

6 (11)

0.20

  Abdominal infection

9 (4)

9 (5)

0 (0)

0.21

  Skin and soft-tissue infection

8 (3)

8 (4)

0 (0)

0.21

 Duration of antibiotic therapy in ICU (days)

16 (9–35)

20 (11–41)

7 (6–14)

 < 0.01

 Antibiotic-free days in ICU (%)

35 (10–52)

29 (9–50)

42 (25–62)

0.01

Bleeding complications

    

 Hemorrhagic shock

22 (8.7)

21 (10.6)

1 (1.9)

0.05

 Intracerebral hemorrhage

5 (2.0)

3 (1.5)

2 (3.7)

0.29

Thrombotic complications

    

 Cannula-associated deep vein thrombosis

69 (36)

45 (31)

24 (49)

0.02

 Limb ischemia

3 (1.2)

3 (1.5)

0 (0)

0.49

 Ischemic stroke

1 (0.4)

1 (0.5)

0 (0)

1.00

Major adverse events

    

 Refractory hypoxemia

15 (5.9)

12 (6.0)

3 (5.6)

1.00

 Cardiac arrest

8 (3.2)

5 (2.5)

3 (5.6)

0.37

 Accidental decannulation

1 (0.4)

0 (0)

1 (1.9)

0.21

  1. Data are presented as numbers of cases (percentage). CTRL, group without extubation during ECMO; ECMO, extracorporeal membrane oxygenation; EXT, group with extubation during ECMO